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Abstract
AIM: Passive immunotherapy using antibody against 
hepatitis B surface antigen (HBsAg) has been advocated 
in certain cases of Hepatitis B infection. We had earlier 
reported on the cloning and expression of a high affinity 
scFv derived from a mouse monoclonal (5S) against 
HBsAg. However this mouse antibody cannot be used 
for therapeutic purposes as it may elicit anti-mouse 
immune responses. Chimerization by replacing mouse 
constant domains with human ones can reduce the 
immunogenicity of this antibody.
METHODS: We cloned the VH and VL genes of this 
mouse antibody, and fused them with CH1 domain 
of human IgG1 and CL domain of human kappa chain 
respectively. These chimeric genes were cloned into a 
phagemid vector. After initial screening using the phage 
display system, the chimeric Fab was expressed in 
soluble form in E. coli . 
RESULTS: The chimeric Fab was purified from the 
bacterial periplasmic extract. We characterized the 
chimeric Fab using several in vitro  techniques and it was 
observed that the chimeric molecule retained the high 
affinity and specificity of the original mouse monoclonal. 
This chimeric antibody fragment was further expressed 
in different strains of E. coli  to increase the yield. 
CONCLUSION: We have generated a mouse-human 
chimeric Fab against HBsAg without any significant loss 
in binding and epitope specificity. This chimeric Fab 
fragment can be further modified to generate a full-
length chimeric antibody for therapeutic uses.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Hepatitis B virus (HBV) infection is the 10th leading 
cause of  death worldwide, with 2 billion people infected 
by it and 350 mill ion suffering from chronic HBV 
infection[1]. Protective antibodies that appear after natural 
infection are mostly directed against the major antigenic 
'a'determinant of  Hepatitis B surface antigen (HBsAg)[2]. 
The immunodominant ‘a’ epitope is a part of  a large 
antigenic area of  HBsAg, called the major hydrophilic 
region[3] and this epitope is present in all serotypes[4]. 
Antibodies against HBsAg are thus advocated for passive 
immunotherapy against Hepatitis B infection in cases of  
accidental needle stick injuries, for liver transplant patients and 
to prevent vertical transfer of  HBV infection from mother 
to child[5-8]. Presently, human anti-HBs immune globulin 
(HBIG) collected from the blood of  hyperimmune donors 
is used for postexposure prophylaxis. Being a blood 
derived product anti-HBs HBIG is costly and can cause 
cross-contamination. Therefore a recombinant antibody to 
HBsAg can be a suitable alternative to such a practice. 
Although several recombinant antibodies against 
HBsAg have been reported in literature, none is available 
for clinical use[9–12]. In our previous work we had expressed 
and characterized a recombinant anti-HBs scFv cloned 
from a mouse monoclonal 5S[13]. This antibody binds to 
HBsAg with high affinity (KD = 0.889 nmol/L). It tested 
positive in an in vitro surrogate test for seroconversion 
and protective antibodies (Hepanostika anti-HBs kit, 
Organon Teknika, The Netherlands). The scFv generated 
from this hybridoma retained the high affinity and 
epitope specificity[13]. However this mouse monoclonal 
cannot be used for therapeutic purposes as it may trigger 
human anti-mouse antibody response, especially when 
multiple infusions are required to obtain therapeutic 
efficacy[14,15]. It is well known that immunogenic reactions 
are predominantly directed towards constant domains of  
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murine antibodies[16]. Problems associated with the HAMA 
response can be reduced by creating mouse-human 
chimeric antibodies, where mouse constant regions are 
replaced by human ones[17-19].
The exact mechanisms of  antibody-mediated virus 
neutralization are not clear ti l l date. A few of  the 
principal mechanisms, which have been postulated for 
virus neutralization, are virus aggregation, inhibition of  
attachment of  virus to cell receptors and inhibition of  
events after attachment to cell receptors[20,21]. Though 
high affinity binding to viral epitopes is a pre-requisite for 
antibody-mediated virus neutralization, the importance 
of  antibody constant domains is not clear. Apart from 
full-length antibodies, antibody Fab fragments have been 
shown to neutralize viruses[22-26]. It has been shown that 
F(ab)2 fragments derived from HBIG is effective for 
the prevention of  vertical transfer of  HBV infection in 
neonates[27]. In comparison to a full-length antibody, a Fab 
fragment can be easily expressed in bacterial expression 
systems[28]. A recombinant Fab can be further modified for 
increase in affinity[29], for chimerization/humanization[30] 
and can be linked with antibody Fc region to generate a 
full-length antibody[31,32].
In the present work, we have fused the variable 
regions of  the mouse monoclonal 5S (IgG1/k) with 
the corresponding human constant regions (CH1 of  
IgG1/CL of  k) to generate a mouse-human chimeric Fab. 
This chimeric Fab was expressed using a phage display 
expression system. After initial screening of  functional 
clones, the chimeric Fab was expressed in E. coli in soluble 
form. It was purified by affinity chromatography and 
characterized for antigen binding. We observed that the 
chimeric Fab fragment retained the high affinity binding 
and epitope specificity of  the original mouse monoclonal. 
This chimeric molecule can be further modified for 
generation of  a therapeutically useful full-length chimeric 
antibody.
MATERIALS AND METHODS
Materials
The phagemid vector pCOMB3H was provided by The 
Scripps Research Institute, La Jolla, USA. Shanta Biotech 
(India) provided purified recombinant HBsAg expressed in 
a Pichia system. E. coli XL1-Blue and TG1 cells and helper 
phage M13 KO7 were obtained from MRC, Cambridge, 
UK. E. coli strains AD494 and BL 21 CodonPlus were 
procured from Novagen. 5S hybridoma cells were 
maintained in RPMI (Sigma, USA) with 10% FCS (Sigma, 
USA). Anti-M13 mouse antibody was provided by Dr. 
Vijay Chaudhary, University of  Delhi, South Campus, New 
Delhi, India.
Construction of the chimeric light chain and Fd fragment
The strategy for generation of  the chimeric Fd and 
light chain is shown in Figure 1. The variable region 
genes of  5S hybridoma were amplified by reverse 
transcription followed by PCR. Primers used for all reverse 
transcriptions and PCRs are listed in Table 1. Total RNA 
was isolated from 5S cells using TRI reagent (Sigma, USA) 
and cDNAs for the VH and VL fragments were generated 
by reverse transcription using Omniscript RTase (Qiagen). 
Primers used for reverse transcriptions were Fd3 and K3 
for VH and VL respectively. These primers have overhangs 
complementary to the 5’ regions of  the respective human 
constant domains. The VH fragment was further amplified 
by PCR using primers 5H23M and Fd3. Similarly, the VL 
fragment was amplified by PCR using primers 5L35 and 
K3. Conditions for both the PCRs were: 30 cycles at 94 °C 
for 1 min, 50 °C for 1 min, 72 °C for 2 min, followed by a 
final extension for 10 min at 72 °C. 
For amplification of  human constant domains, RNA 
was isolated from human peripheral blood lymphocytes 
(PBLs) using TRI reagent. cDNAs for the CH1 region of  
human IgG1 and the CL region of  human kappa chain 
were generated by reverse transcription using Omniscript 
RTase (Qiagen). Primers used for reverse transcriptions 
were CG1Z and Ck1d for CH1 and CL respectively. The 
CH1 fragment was further amplified by PCR using primers 
Fd5 and CG1Z. Human CL was amplified by PCR using 
primers K5 and Ck1d. Fd5 and K5 carry overhangs 
complementary to the 3’ end of  variable regions of  5S. 
Conditions for both these PCRs were: 30 cycles at 94 °C 
for 1 min, 60 °C for 1 min, 72 °C for 2 min, followed by a 
final extension for 10 min at 72 °C. 
PCR amplified fragments were resolved in 1.5% 
agarose gel and respective bands were eluted out using 
QIAquick gel extraction kit (Qiagen). PCR amplified CH1 
(human IgG1) and mouse VH were used as templates for 
generation of  the chimeric Fd by overlap PCR. Initial 
assembly of  equimolar amounts of  the mouse VH and 
human CH1 was done by PCR for 20 cycles at 94 °C for 
                  Primer                                                                                                              Sequence
5’ primer for VH (5H23M)                             5’- AG GTC CAG CTT CTC GAG CCC GGG GC -3’
3’ primer for VH (Fd3)                                    5’-CGA TGG GCC CTT GGT GGA GGC TGA AGA GAC AGT GAC TGA GGT TCC-3’
5’ primer for CH1 of human IgG1 (Fd5)         5’-GGA ACC TCA GTC ACT GTC TCT TCA GCC TCC ACC AAG GGC CCA TCG-3’
3’ primer for CH1 of human IgG1 (CG1Z)         5’- GCA TGT ACT AGT TTT GTC ACA AGA TTT GGG -3’
5’ primer for VL (5L35)                                                  5’-CCA GAT GTG AGC TCG TGA TGA CCC AGA CTC CA-3’
3’ primer for VL (K3)                                                  5’-CAG ATG GTG CAG CCA CAG TCC GTT TGA GTT CCA GCT TGG-3’
5’ primer for CL of human k chain (K5)        5’-CCA AGC TGG AAC TCA AAC GGA CTG TGG CTG CAC CAT CTG-3’
3’ primer for CL of human k chain (Ck1d)         5’- GCG CCG TCT AGA ATT AAC ACT CTC CCC TGT TGA AGC TCT TTG TGA CGG GCG AAC TCA G -3’
Table 1 Oligonucleotide primers used for generation of the chimeric Fd and light chain
Primer names are given in parenthesis. Sites for restriction enzymes are shown as underlined. Complementary overhangs are shown in bold letters.
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after overnight incubation and screened for the presence 
of  the insert by colony PCR and restriction digestion 
(Xho1/Spe1). The recombinant phagemid pCOMB3H-Fd 
was isolated by alkali-lysis method and digested with Sac1 
and Xba1. The chimeric light chain digested with these two 
enzymes was cloned into pCOMB3H-Fd to generate the 
phagemid construct pCOMB3H-Fd-L. This construct was 
transformed into chemically competent XL1-Blue cells 
by standard chemical transformation method and after 
overnight incubation, recombinant clones were checked 
for the presence of  the chimeric light chain by colony PCR 
and by restriction digestion (Sac1/Xba1).
Expression of the phage antibody and selection of antigen 
binding clones
Cells transformed with the construct pCOMB3H-Fd-L 
were used for expression of  the chimeric Fab on phage 
surface. Phage displaying chimeric Fab was rescued by 
infection with helper phage M13-KO7 as described by 
1 min, 60 °C for 1 min and 72 °C for 2 min, followed by 
final extension of  10 min at 72 °C. The product of  the 
initial assembly reaction was diluted 10 times and used as 
the template for pull through PCR using primers 5H23M 
and CG1Z. Similarly human kappa CL and mouse VL 
fragment were joined to generate the chimeric light chain. 
Primers used for this reaction were 5L35 and Ck1d. 
Construction of the phagemid construct
We used the bi-cistronic phagemid vector pCOMB3H, a 
variant of  the phagemid pComb3[33], for the expression 
of  the chimeric Fab. The essential features of  this vector 
system and our cloning strategy are shown in Figure 1. 
The chimeric Fd was digested with Xho1 and Spe1 and 
cloned into the phagemid vector pCOMB3H. The 
resulting construct (pCOMB3H-Fd) was transformed into 
chemically competent E. coli XL1-Blue cells by standard 
chemical method (CaCl2/heat shock)[34]. Transformed cells 
were grown on Amp-Agar plates. Colonies were picked up 
←
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Figure 1 Schematic representation of the strategy for cloning and expression of the anti-HBs chimeric Fab. The VH and VL fragments of 5S hybridoma were fused with 
human CH1 and CL by overlap PCR. The resulting chimeric fragments were cloned in the bi-cistronic phagemid vector pCOMB3H. Both the fragments are under the control 
of a single LacZ promoter. ompA and pelB are two leader sequences, provided for directing the light chain and Fd fragment to the bacterial periplasm. Two ribosome-
binding sites are present in the vector for stable expression of both the fragments. The Fd fragment was cloned upstream to the phage gIII sequence, for surface display of 
the chimeric Fab. This gIII fragment was removed by digestion with Spe I/Nhe I and after self-ligation of the vector, the Fab fragment was expressed in soluble form.
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Barbas et al.[33]. Phage was precipitated from the culture 
supernatant by incubating with PEG/NaCl (20% 
PEG/2.5 mol/L NaCl) for 8 h on ice. After centrifugation, 
precipitated phage was resuspended in PBS and titrated to 
determine phage concentration[35]. 
Clones displaying functional Fab fragment were 
selected by biopanning over antigen-coated plates. The 
method for biopanning has been discussed in detail in 
our earlier article[13]. Essentially this method involves 
incubation of  phage in uncoated ELISA plate followed 
by incubation of  unbound phage in antigen-coated plate. 
After thorough washing, bound phage was eluted out 
at low pH. Eluted phage was passed through two more 
rounds of  selection over coated and uncoated wells with 
increasing number of  washing.
Identification of antigen binding clones by phage-ELISA 
Phage obtained after three rounds of  selection, was 
reinfected in XL1-Blue cells and amplified by standard 
phage rescue protocol as mentioned earlier. Antigen 
binding clones were identified by phage-ELISA. Maxisorp 
ELISA plates were coated with HBsAg (250 ng/well) in 
bicarbonate buffer (pH 9.5). After blocking with 2% non-
fat milk in PBS (MPBS), phage (~1012/well) was added 
and incubated for 1 h at room temperature. Bound phage 
was detected by incubation with 1:1 000 dilution of  
anti-M13 mouse antibody for 1 h at room temperature, 
followed by 1 h incubation with 1:2 000 dilution of  
anti-mouse antibody-HRP conjugate (Promega, USA). 
ELISA was developed by using 100 μL of  0.4 mg/mL 
o-phenylenediamine and 0.8 µL/mL of  H2O2 in citrate-
phosphate buffer (pH 5). The same amount of  helper 
phage (M13-KO7) was used as negative control in phage-
ELISA.
The phagemid construct was isolated from the clone 
showing maximum binding and the nucleotide sequences 
of  the chimeric Fd and light chain were determined by 
sequencing using ABI-Prism automatic DNA sequencer. 
Primers used for sequencing the l ight chain were 
5’-ATGAAAAAGACAGCTATCGC-3’ and 5’-TAATAAC
AATCCAGCGGCTG-3’. Primers used for sequencing the 
Fd fragment were 5’-TCTTTTCATAATCAAAATCACC
G-3’ and 5’-AAATGAAATACCTATTGCC-3’.
Soluble expression of the chimeric Fab 
The antigen binding clone selected by phage ELISA was 
further processed for soluble expression of  the anti-HBs 
chimeric Fab. For soluble expression of  the chimeric 
Fab, the phage gIII sequence was removed from the 
recombinant phagemid construct pCOMB3H-Fd-L by 
double digestion with Spe I and Nhe I. Digestion by these 
two enzymes provides compatible ends for self-ligation 
of  the vector. Double digested phagemid was self-ligated 
to generate the construct pCOMB3H-Fd-L-Sol and 
transformed in chemically competent XL1-Blue cells. For 
soluble expression of  recombinant chimeric Fab, 1 L Super 
Broth with 20 mmol/L MgCl2 and ampicillin (100 µg/mL) 
was inoculated with 10 mL of  overnight culture of  the 
recombinant clone and grown at 37 °C till the A600 reached 
approximately 0.6, when overexpression of  the chimeric 
Fab was induced by 1 mmol/L IPTG. After overnight 
growth at 30 °C, cells were harvested by centrifugation at 
4 000 r/min. Cell pellet was re-suspended in 20 mL PBS/ 
1 mmol/L EDTA and kept on ice for 40 min. Clarified 
periplasmic extract was obtained by centrifugation of  the 
re-suspended product at 10 000 g. The same method was 
used to express the soluble chimeric Fab in three other E. 
coli strains (AD494, BL21 CodonPlus and TG1).
Purification of the recombinant chimeric Fab
The periplasmic extract was concentrated (~10 times) 
using Centriprep YM-30 centrifugal filter (Millipore, 
USA). The recombinant chimeric Fab was purified from 
the periplasmic extract by affinity chromatography using 
HiTrap Protein G HP column (Amersham) as per the 
manufacturer’s protocol. In brief, the protein G column 
(1 mL) was washed thoroughly with double distilled water 
(five column volumes) and equilibrated with five column 
volumes of  equilibration buffer (pH 7.0). The concentrated 
periplasmic extract was allowed to pass through the column 
using a syringe at a speed of  2 mL/min. The column was 
washed thoroughly by 10 volume of  equilibration buffer 
and bound chimeric Fab was eluted out by 5 volume of  
elution buffer (pH 2.7). Eluted fractions were immediately 
neutralized using neutralization buffer (77 µL/mL, pH 9). 
The eluted fractions were concentrated by Centriprep 
YM-30 centrifugal filter and checked on SDS-PAGE.
Electrophoresis and Western blot analysis
The purified chimeric Fab was resolved by 12% SDS-
PAGE, separately in reducing (with bME) and non-
reducing conditions (without bME or DTT). The resolved 
protein was stained by silver staining. 
For Western blot analysis, the concentrated periplasmic 
extract was resolved by 12% SDS-PAGE in non-reducing 
conditions and electroblotted on nitrocellulose membrane. 
After blocking with 4% MPBS for 2 h, the chimeric Fab 
was detected by Rabbit anti-Human IgG-HRP conjugate 
(1:1 000 dilution; Dako). The blot was developed using 
DAB/H2O2 system. An equal amount of  concentrated 
periplasmic extract of  untransformed XL1-Blue cells 
was used as the negative control for the Western blot 
experiment. A separate Western blot experiment was 
performed under reducing conditions for the detection 
of  the monomeric Fd and light chain. Whenever required, 
intensity of  bands in Western blots was measured 
densitometrically using ChemiImager 4400 (Alpha 
Innotech Corp., USA).
Antigen binding assays for the chimeric Fab
Binding of  the chimeric Fab was checked by solid 
phase ELISA. Maxisorp ELISA plate was coated with 
250 ng/well of  HBsAg in bicarbonate buffer (pH 9.5). 
After blocking with 4% MPBS, different dilutions of  
the chimeric Fab was added to antigen coated wells and 
bound antibodies were detected by Rabbit anti-Human 
IgG-HRP conjugate (1:2 000 dilution; Dako). Hybridoma 
supernatant of  the original mouse monoclonal 5S was 
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used as a positive control for this experiment. The extract 
of  untransformed XL1-Blue cells was used as a negative 
control and corresponding readings were deducted from 
the readings of  the chimeric Fab. This ELISA method was 
also used to study the levels of  expression the chimeric 
Fab in different E. coli strains.
For competitive ELISA, plates were coated with HBsAg 
(100 ng/well) in bicarbonate buffer and blocked with 
4% MPBS. Different amounts of  the chimeric Fab were 
mixed with 1:80 dilution of  5S hybridoma supernatant and 
added to antigen-coated wells. After one hour incubation 
at room temperature, bound mouse antibody was detected 
by anti-mouse-HRP conjugate (Bangalore Genei, India). 
Periplasmic extract of  untransformed XL1-Blue cells was 
used as the negative control and binding of  the mouse 
monoclonal in its presence was taken as the maximum 
binding to calculate the percent inhibition. 
Determination of the dissociation constant of the chimeric Fab
The dissociation constant (KD) of  HBsAg and chimeric 
Fab interaction was determined in solution phase by an 
ELISA method as described by Friguet et al.[36]. Essentially 
the technique involves incubation of  a fixed amount of  the 
antibody with different amounts of  the antigen in solution 
phase for a prolonged period so that the equilibrium 
is reached. This is followed by detection of  unbound 
antibody by conventional ELISA. This ELISA data is 
then used to calculate the KD value, by using an equation 
derived from the law of  mass action. The advantage of  
this technique is that it can be used to determine the 
affinity of  an antibody without prior purification. 
For this experiment we used crude periplasmic extract 
of  the clone expressing the chimeric Fab in soluble form. 
A fixed amount of  the periplasmic extract (1:300 dilution, 
in 100 µL of  4% MPBS) was incubated with varying 
concentrations of  HBsAg (3-10 nmol/L) for 16 h at 4 °C. 
This equilibrated solution was incubated in antigen coated 
ELISA plates (250 ng antigen/well) for 20 min at room 
temperature to capture the free Fab. Bound chimeric Fab was 
detected by Rabbit anti-human IgG-HRP conjugate (Dako). 
Protein estimation 
Protein concentrations were estimated by Bradford 
assay[37]. 
RESULTS
Generation of  a phagemid construct for the expression 
of  phage antibody: Variable regions of  the light chain 
and heavy chain of  the mouse monoclonal 5S were 
amplified by RT-PCR. The CH1 region of  human IgG1 
and CL of  human kappa chain were amplified by RT-PCR 
using RNA extracted from human PBLs. After the fusion 
of  the mouse VH and human CH1, resulting chimeric 
Fd was cloned into the phagemid vector pCOMB3H 
to generate the recombinant construct pCOMB3H-Fd. 
Similarly, the chimeric light chain, generated by joining the 
mouse VL and human CL, was cloned into pCOMB3H-Fd 
to generate the recombinant construct pCOMB3H-Fd-L. 
This construct was transformed in XL1-Blue cells and 
phage displaying the chimeric Fab was generated by phage 
rescue using helper phage. 
Selection of  antigen binding clones and phage ELISA: 
The anti-HBs chimeric Fab was first expressed as phage 
antibody and antigen-binding clones were enriched by bio-
panning over antigen coated plate. Selection was done on 
uncoated and antigen coated wells alternatively, thereby 
removing plastic binding clones, which can interfere in 
subsequent ELISAs. After three rounds of  selection, 
functional clones were amplified and rescued to generate 
phage particles displaying the chimeric Fab and antigen-
binding clones were detected by phage ELISA (Figure 2). 
As shown in Figure 2, clone 1 had the maximum binding 
and was used for soluble expression of  the chimeric Fab. 
Nucleotide sequences of  the chimeric Fd and light chain 
of  this clone were submitted to the EMBL Nucleotide 
Sequence Database (EMBL accession numbers: AJ878860 
and AJ878861). Sequence analysis indicated that the variable 
regions in these chimeric genes are identical to the variable 
regions of  the mouse monoclonal 5S (data not shown).
Soluble expression of  the chimeric Fab: Phage gIII 
sequence was removed from pCOMB3H-Fd-L for soluble 
expression of  the chimeric Fab. The anti-HBs chimeric 
Fab was expressed in E. coli XL1-Blue cells by inducing 
overnight with 1 mmol/L IPTG. The leader sequences, 
present upstream to the chimeric genes, drag both the 
chains to the bacterial periplasm, where they form inter- 
and intra-chain disulphide bonds. The periplasmic extract 
was concentrated and the chimeric Fab was purified 
using Protein G column. Yield of  the purified chimeric 
Fab when expressed in XL1-Blue cells was ~40 µg/L 
of  culture. The purified product was resolved by SDS-
PAGE in non-reducing (without bME/DTT) as well as in 
reducing conditions (with bME). As shown in Figure 3A, 
the chimeric Fab is expressed as a heterodimer (~50 ku) 
of  the chimeric Fd and light chain. In reducing conditions, 
both the chains were detected in monomeric form 
(~25 ku).
Expression of  the heterodimeric chimeric Fab was 
further confirmed by Western blot in non-reducing 
0.8
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0.4
1.4
0.2
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0.0
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Figure 2 Phage ELISA to identify antigen binding clones. After three rounds 
of biopanning, selected phage was rescued and antigen-binding clones were 
detected by phage ELISA. In this experiment 5S hybridoma supernatant and 
helper phage M13 KO7 were used as positive (+) and negative (–) control 
respectively. Clone 1 was used for soluble expression of the chimeric Fab.
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conditions (Figure 3B, lane NR). In reducing conditions a 
band corresponding to monomeric Fd and/light chain was 
detected (Figure 3B, lane R).
Binding properties of  the chimeric Fab: Binding of  the 
chimeric Fab was detected by solid phase ELISA and the 
result is shown in Figure 4A. As shown in Figure 4A, the 
binding of  the antibody increases with increasing amount 
of  the chimeric Fab, reaching a saturation level as expected 
for antigen-antibody interactions.
Competitive ELISA was performed to confirm that 
chimerization has not disturbed the epitope specificity of  
the chimeric Fab fragment. For competitive ELISA, the 
parent mouse monoclonal 5S was used to compete with 
varying concentrations of  the chimeric Fab and binding of  
the mouse antibody was detected using anti-mouse-HRP 
conjugate. Figure 4B shows that the chimeric Fab inhibits 
the binding of  the mouse antibody, indicating that both of  
these bind to the same epitope.
Dissociation constant of  the chimeric Fab: The 
dissociation constant of  the chimeric Fab in solution 
phase was determined using an ELISA based technique 
developed by Friguet et al.[36]. As calculated from the slope 
97 ku
68 ku
43 ku
29 ku
F d/L
NR R
→Fab
B
Figure 3 SDS-PAGE (A) and Western Blot (B) analysis of the chimeric Fab. The purified chimeric Fab was resolved in 12% SDS-PAGE under reducing (R) and non-
reducing conditions (NR). In non-reducing conditions the Fab is a heterodimer of molecular weight ~50 ku. In reducing conditions the heterodimer dissociates into chimeric 
light chain (~25 ku) and Fd (~25 ku). Both the gels were stained by silver staining. M is the lane for the protein marker. Similar observations were made in Western Blots (B) 
of the chimeric Fab in reducing (R) and non-reducing (NR) conditions. Electroblotted antibody fragments were detected by Rabbit anti-Human IgG-HRP conjugate (1:1 000 
dilution; Dako). 
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cannot be used clinically. HAMA may neutralize the 
injected mouse antibody directly by immune complex 
formation, which could lead to rapid clearance or to 
hypersensitivity reactions[38,39]. As immunogenic reactions 
are predominantly directed towards the Fc region of  
murine antibodies[16], creation of  mouse-human chimeric 
antibodies by swapping murine constant regions with the 
human ones can address the problem of  HAMA response, 
at least in part[17-19]. But such domain swapping can alter 
the immunological and pharmacokinetic properties of  
an antibody, making the task of  generation of  chimeric 
antibodies quite tricky[40].
One of  the crucial aspects in generation of  chimeric 
antibodies is the selection of  human isotypes for domain 
swapping. Effector functions of  antibody constant 
domains are broadly dependent on the antibody classes 
and subclasses[41]. Usually human IgG1 is the preferred 
choice for chimeric antibodies in situations where 
activation of  effector functions is the desired outcome[42]. 
Rath and Devey[43] had observed that the subclasses of  
antibodies associated with HBsAg in circulating immune 
complexes of  patients with either acute or chronic HBV 
infections were predominantly IgG1 and IgG4. A study 
involving children, who have recovered from acute 
hepatitis B, has shown that after natural seroconversion, 
specific antibodies were highly restricted to IgG1[44]. It has 
also been observed that anti-HBs IgG1 is predominant 
after vaccination with recombinant vaccines[44,45].
Apart from being important for effector functions, the 
choice of  isotype can also affect the antigen binding of  
a chimeric molecule. It has been observed that changes 
in constant domains can affect the functional affinity and 
specificity of  antibodies[46]. Pritsch et al.[47] have shown 
that Fab fragments of  antibodies sharing identical variable 
regions but CH1 of  different isotypes have significant 
differences in affinities. A molecular dynamic study 
of  the line in Figure 5, the KD of  the chimeric anti-HBs 
Fab is 8.166±0.14 nmol/L, (r2 = 0.914).
Expression of  the chimeric Fab in different E.coli 
strains: Yield of  this chimeric Fab in E. coli XL1-Blue 
cells was found to be low (~40 µg/L). The recombinant 
construct pCOMB3H-Fd-L-Sol was transformed into 
three other strains of  E. coli, (AD494, BL21 CodonPlus 
and TG1) to check the yield of  the chimeric Fab in 
soluble form. The chimeric Fab was expressed in these 
cells in the same fashion as stated above for XL1-Blue 
cells. The levels of  expression of  the chimeric Fab in 
different E. coli strains were checked by Western Blot and 
compared densitometrically (Figures 6A and B). The levels 
of  expression of  the chimeric Fab in different strains 
of  E. coli were further confirmed by ELISA using crude 
periplasmic extracts. The result of  the ELISA is shown in 
Figure 6C. Yields of  the purified chimeric Fab expressed 
in different E. coli strains are shown in Table 2. As shown 
in Figure 6 and Table 2, maximum yield of  the chimeric 
Fab was observed in case of  E. coli AD494 cells.
DISCUSSION 
5S is a mouse monoclonal that binds to HBsAg with high 
affinity[13]. However, like any other mouse monoclonal, 
this antibody can give rise to HAMA response and 
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Figure 6 Expression profile of the chimeric Fab in different strains of E. coli. The chimeric Fab was expressed in soluble form in different E. coli strains in identical 
conditions. Levels of expression of the chimeric Fab were checked by Western blot in non-reducing conditions (A). Intensities of bands were measured densitometrically (B). 
Levels of expression were also checked by ELISA (C). Equal amount of the periplasmic extracts were allowed to bind to HBsAg coated on ELISA plate and bound chimeric 
Fab was detected. (XL1 = XL1-Blue, AD494 = AD494, COD+ = BL21 Codon Plus, TG1 = TG1, IDV = integrated density value).
Table 2 Yields of the anti-HBs chimeric Fab in different E. coli 
strains
                          E. coli strain                      Yield (µg/L)1
                           XL1-Blue                                40
                           AD494                                                     62
                           BL21 Codon Plus                                40
                           TG1                                                      8
1Estimated by Bradford assay, after purification by protein G column
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was transformed in different E. coli strains — TG1, AD 
494 and BL21 CodonPlus. E. coli BL21 CodonPlus-RP 
(Novagen) cells contain extra copies of  the argU and proL 
genes. These genes encode tRNAs that recognize the 
arginine codons AGA, AGG and the proline codon CCC, 
respectively. E. coli BL21 has been used for high-level 
expression of  several antibody fragments[56,57]. E. coli AD494 
cells are thioredoxin negative (trxB–), thereby providing an 
oxidizing environment in the cytoplasm. Proper folding 
and assembly of  antibody domains require inter- and intra-
chain disulphide bond formation. Therefore bacterial 
periplasm is suitable for the assembly of  functional Fab 
fragments. An oxidizing environment in the cytoplasm 
may also help to increase the yield of  properly folded 
soluble antibody fragments. We expressed the anti-HBs 
chimeric Fab in soluble form in different E. coli strains 
under identical conditions. As shown in Figure 6 and 
Table 2, there was a slight increase in the expression of  
the chimeric Fab in AD494 cells; whereas the expression 
in BL21 was equivalent to that in XL1-Blue cells. Though 
Raffai et al.[55] had observed increased yield of  soluble Fab 
fragment in TG1 in comparison to XL1-Blue cells, we 
could not detect any such increase in yield. 
Though chimerization and humanization are essential 
to reduce immunogenicity of  non-human antibodies 
before they can be used clinically such genetic engineering 
can alter functional capabilities of  the molecule, often 
leading to loss of  binding or reduction in affinity. Our 
results show that the chimerization of  the 5S mouse 
monoclonal did not disturb its binding to the antigen 
and the chimeric Fab binds to the same epitope as that 
of  the original mouse monoclonal. Though chimeric and 
monovalent in nature, the affinity of  the recombinant 
chimeric Fab remained in the same range as the mouse 
monoclonal 5S. The high affinity binding of  this chimeric 
Fab fragment indicates that it can be further modified to 
generate a clinically applicable full-length chimeric anti-
HBs antibody, with out any significant loss of  binding 
affinity. 
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